The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
Abstract
The present study compared foscarnet with ganciclovir for preemptive therapy of cytomegalovirus (CMV) infection after allogeneic blood or marrow stem cell transplantation (SCT). Patients with CMV infection, as detected by weekly antigenemia or polymerase chain reaction (PCR) in blood leukocytes, were randomized to intravenous therapy for 2 weeks with either foscarnet at 60 mg/kg or ganciclovir at 5 mg/kg administered every 12 hours; if CMV infection remained detectable, patients received an additional 2 weeks of intravenous foscarnet at 90 mg/kg or ganciclovir at 6 mg/kg given once daily for 5 days per week, after which therapy was stopped. Primary efficacy endpoint was the occurrence of CMV disease or death from any cause within 180 days after SCT. A total of 213 patients were treated with either foscarnet (n = 110) or ganciclovir (n = 103). Kaplan-Meier estimates of event-free survival within 180 days after SCT were similar in the 2 treatment groups (P =.6). During study treatment, severe neutropenia (< 0.5 x 10(9)/L) occurred in 11 (11%) patients on ganciclovir versus 4 (4%) patients on foscarnet (P =.04), and impaired renal function was observed in 5 (5%) patients on foscarnet versus 2 (2%) patients on ganciclovir (P =.4). Neutropenia or thrombocytopenia required discontinuation of ganciclovir in 6 (6%) patients but in no foscarnet-treated patient (P =.03). After allogeneic SCT, preemptive therapy of CMV infection with foscarnet shows similar efficacy as with ganciclovir, but is associated with a lower proportion of patients who develop severe neutropenia and who require discontinuation of antiviral therapy due to hematotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Rheinwatd, J. G., & Green, H. (1975) · Cell · doi:10.1016/s0092-8674(75)80001-8 · Cited by 4,537
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Changes in keratin gene expression during terminal differentiation of the keratinocyte
Fuchs, E., & Green, H. (1980) · Cell · doi:10.1016/0092-8674(80)90094-x · Cited by 1,063
Methods for growth of cultured cells in serum-free medium
Barnes, D., & Sato, G. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90151-7 · Cited by 1,002
Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation
Meyers, J. D., Flournoy, N., & Donnall Thomas, E. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/153.3.478 · Cited by 776
Reusser, P., Riddell, Sr., Meyers, J., & Greenberg, P. (1991) · Blood · doi:10.1182/blood.v78.5.1373.1373 · Cited by 666
Self-citationGanciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant
Goodrich, J. M., Bowden, R. A., Fisher, L., Keller, C., Schoch, G., & Meyers†, J. D. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00003 · Cited by 650
Schmidt, G. M., Horak, D. A., Niland, J. C., Duncan, S. R., Forman, S. J., Zaia, J. A., & the City of Hope–Stanford–Syntex CMV Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199104113241501 · Cited by 616
Goodrich, J. M., Mori, M., Gleaves, C. A., Du Mond, C., Cays, M., Ebeling, D. F., Buhles, W. C., DeArmond, B., & Meyers, J. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252303 · Cited by 599
Cited by
Antiviral drugs for cytomegalovirus diseases
Biron, K. K. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.002 · Cited by 468
Boeckh, M., Nichols, W. G., Papanicolaou, G., Rubin, R., Wingard, J. R., & Zaia, J. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(03)00287-8 · Cited by 431
Ljungman, P., de la Camara, R., Cordonnier, C., Einsele, H., Engelhard, D., Reusser, P., Styczynski, J., Ward, K., & Leukemia, F. T. E. C. O. I. I. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.162 · Cited by 291
Self-citationSegal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R. (2007) · Clinical Infectious Diseases · doi:10.1086/510677 · Cited by 168
Metadata
- Authors
- Reusser, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-02-15
- Volume
- 99
- Issue
- 4
- Pages
- 1159-1164
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2112067138
- Cited by
- 326
- References
- 30
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. https://app.cochat.ai/papers/10.1182/blood.v99.4.1159
- The paper
- Reusser, P. (2002). Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. https://doi.org/10.1182/blood.v99.4.1159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.